BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37810628)

  • 21. Evaluation of the Selectivity of Several Organic Anion Transporting Polypeptide 1B Biomarkers Using Relative Activity Factor Method.
    Chan GH; Houle R; Zhang J; Katwaru R; Li Y; Chu X
    Drug Metab Dispos; 2023 Sep; 51(9):1089-1104. PubMed ID: 37137718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Role of Coproporphyrins As Endogenous Biomarkers for Organic Anion Transporting Polypeptide 1B Inhibition-Progress from 2016 to 2023.
    Lai Y
    Drug Metab Dispos; 2023 Aug; 51(8):950-961. PubMed ID: 37407093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors Influencing Plasma Coproporphyrin-I Concentration as Biomarker of OATP1B Activity in Patients With Rheumatoid Arthritis.
    Ono H; Tanaka R; Suzuki Y; Oda A; Ozaki T; Tatsuta R; Maeshima K; Ishii K; Ohno K; Shibata H; Itoh H
    Clin Pharmacol Ther; 2021 Oct; 110(4):1096-1105. PubMed ID: 34319605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Investigation of Coproporphyrins as Sensitive Biomarkers to Predict Mild to Strong OATP1B-Mediated Drug-Drug Interactions.
    Kunze A; Ediage EN; Dillen L; Monshouwer M; Snoeys J
    Clin Pharmacokinet; 2018 Dec; 57(12):1559-1570. PubMed ID: 29663259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endogenous Coproporphyrin I and III are Altered in Multidrug Resistance-Associated Protein 2-Deficient (TR
    Bezençon J; Saran C; Hussner J; Beaudoin JJ; Zhang Y; Shen H; Fallon JK; Smith PC; Meyer Zu Schwabedissen HE; Brouwer KLR
    J Pharm Sci; 2021 Jan; 110(1):404-411. PubMed ID: 33058892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3.
    Yoshikado T; Toshimoto K; Maeda K; Kusuhara H; Kimoto E; Rodrigues AD; Chiba K; Sugiyama Y
    CPT Pharmacometrics Syst Pharmacol; 2018 Nov; 7(11):739-747. PubMed ID: 30175555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship of plasma 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid concentration with OATP1B activity in patients with chronic kidney disease.
    Ono H; Tanaka R; Suzuki Y; Oda A; Sato H; Tatsuta R; Ando T; Shin T; Ohno K; Itoh H
    Clin Transl Sci; 2024 Feb; 17(2):e13731. PubMed ID: 38564661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cluster Gauss-Newton method analyses of PBPK model parameter combinations of coproporphyrin-I based on OATP1B-mediated rifampicin interaction studies.
    Yoshikado T; Aoki Y; Mochizuki T; Rodrigues AD; Chiba K; Kusuhara H; Sugiyama Y
    CPT Pharmacometrics Syst Pharmacol; 2022 Oct; 11(10):1341-1357. PubMed ID: 35945914
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition.
    Gu X; Wang L; Gan J; Fancher RM; Tian Y; Hong Y; Lai Y; Sinz M; Shen H
    Drug Metab Dispos; 2020 Aug; 48(8):724-734. PubMed ID: 32482623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct assay of uroporphyrin and coproporphyrin in human urine by reverse-mode field amplified sample injection-sweeping and micellar electrokinetic chromatography.
    Chen YL; Huang YC; Wang CC
    Talanta; 2015 Oct; 143():27-34. PubMed ID: 26078124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Results From Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Inhibitory Effect of Finerenone on the Drug Transporters BCRP, OATP1B1, and OATP1B3.
    Heinig R; Fricke R; Wertz S; Nagelschmitz J; Loewen S
    Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):803-815. PubMed ID: 36029368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug-Drug Interaction and Associated Biomarker Levels in Healthy Volunteers.
    Yee SW; Giacomini MM; Shen H; Humphreys WG; Horng H; Brian W; Lai Y; Kroetz DL; Giacomini KM
    Clin Transl Sci; 2019 Jul; 12(4):388-399. PubMed ID: 30982223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Isolated Perfused Rat Liver Model: Simultaneous LC-MS Quantification of Pitavastatin, Coproporphyrin I, and Coproporphyrin III Levels in the Rat Liver and Bile.
    Izat N; Kaplan O; Çelebier M; Sahin S
    ACS Omega; 2024 Apr; 9(17):19250-19260. PubMed ID: 38708282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biomarker-Informed Model-Based Risk Assessment of Organic Anion Transporting Polypeptide 1B Mediated Drug-Drug Interactions.
    Kimoto E; Costales C; West MA; Bi YA; Vourvahis M; David Rodrigues A; Varma MVS
    Clin Pharmacol Ther; 2022 Feb; 111(2):404-415. PubMed ID: 34605015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repression of Organic Anion Transporting Polypeptide (OATP) 1B Expression and Increase of Plasma Coproporphyrin Level as Evidence for OATP1B Downregulation in Cynomolgus Monkeys Treated with Chenodeoxycholic Acid.
    Zhang Y; Chen SJ; Chen C; Chen XQ; Chatterjee S; Shuster DJ; Dexter H; Armstrong L; Joshi EM; Yang Z; Shen H
    Drug Metab Dispos; 2022 Aug; 50(8):1077-1086. PubMed ID: 35636769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Organic Anion-Transporting Polypeptide Genes Are Not Induced by the Pregnane X Receptor Activator Rifampin: Studies in Hepatocytes In Vitro and in Monkeys In Vivo.
    Niu C; Wang Y; Zhao X; Tep S; Murakami E; Subramanian R; Smith B; Lai Y
    Drug Metab Dispos; 2019 Dec; 47(12):1433-1442. PubMed ID: 31582395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and validation of LC-MS/MS methods for the quantification of 101BHG-D01, a novel, long-acting and selective muscarinic receptor antagonist, and its main metabolite M6 in human plasma, urine and feces: Application to a clinical study in healthy Chinese subjects.
    Gao H; Cheng M; Liu H; Ding L
    J Pharm Biomed Anal; 2023 Sep; 233():115498. PubMed ID: 37285657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physiologically-based pharmacokinetic model-based translation of OATP1B-mediated drug-drug interactions from coproporphyrin I to probe drugs.
    Mochizuki T; Aoki Y; Yoshikado T; Yoshida K; Lai Y; Hirabayashi H; Yamaura Y; Rockich K; Taskar K; Takashima T; Chu X; Zamek-Gliszczynski MJ; Mao J; Maeda K; Furihata K; Sugiyama Y; Kusuhara H
    Clin Transl Sci; 2022 Jun; 15(6):1519-1531. PubMed ID: 35421902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive Evaluation of the Utility of 20 Endogenous Molecules as Biomarkers of OATP1B Inhibition Compared with Rosuvastatin and Coproporphyrin I.
    Barnett S; Ogungbenro K; Ménochet K; Shen H; Humphreys WG; Galetin A
    J Pharmacol Exp Ther; 2019 Jan; 368(1):125-135. PubMed ID: 30314992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Various effects of repeated rifampin dosing on coproporphyrin levels in humans.
    Kinzi J; Grube M; Brecht K; Seibert I; Siegmund W; Meyer Zu Schwabedissen HE
    Clin Transl Sci; 2023 Nov; 16(11):2289-2298. PubMed ID: 37705216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.